stockrow
Saturday 7 November 2026
Export KURA’s income statement to Excel — free account
Kura Oncology, Inc.
KURA Healthcare Biotechnology
Kura Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.5 million, up 25.2% from fiscal 2024.
- Revenue
- +36.5%
- EPS
- −2.67%
- Free cash flow
- −109.1%
- Total debt
- +1.76%
Quarter to June 2026, against a year earlier
7.22
0.42
+6.18%
Follow KURA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 54 | 67 | 77 | +25.2% | 96 | 209 | 286 | +61.9% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 100.00 | 99.92 | 99.35 | +99.9 pt | ||||||
| EBT | (28) | (35) | (60) | (63) | (90) | (130) | (136) | (153) | (172) | (278) | (297) | +29.3% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (319.15) | (412.51) | (384.19) | (412.5) pt | ||||||
| Net income | (28) | (35) | (60) | (63) | (90) | (130) | (136) | (153) | (174) | (279) | (297) | +29.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.63 | 0.77 | 0.87 | n/m | |||||
| Earnings | (1.47) | (1.52) | (1.72) | (1.51) | (1.69) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) | (3.37) | +9.0% | ||||||
| Cash flow | (1.36) | (1.22) | (1.38) | (1.31) | (1.32) | (1.58) | (1.64) | (1.70) | 1.56 | (0.73) | (1.26) | (6.6%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | (0.04) | (0.02) | (0.01) | 0.00 | (0.01) | (0.08) | (0.06) | n/m | ||||||
| Free cash flow | (1.36) | (1.22) | (1.38) | (1.31) | (1.36) | (1.59) | (1.65) | (1.71) | 1.55 | (0.81) | (1.32) | (5.6%) | ||||||
| Book value | 3.04 | 3.44 | 4.57 | 5.22 | 11.51 | 7.64 | 6.27 | 5.43 | 4.80 | 1.99 | 0.55 | (4.6%) | ||||||
| Shares, m | 19 | 23 | 35 | 42 | 53 | 66 | 67 | 73 | 86 | 88 | 88 | +18.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 13.50 | 8.31 | 6.7 | ||||||
| P/B | — | — | — | — | — | — | — | — | 1.81 | 5.23 | 13.25 | 3.5 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 3.82 | 1.71 | 1.9 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.24 | (3.65) | (1.13) | (1.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (25) | (28) | (49) | (55) | (70) | (105) | (110) | (125) | 134 | (64) | (112) | +10.8% | |||||
| Capex | — | — | — | — | (2) | (1) | (1) | 0 | 0 | (7) | (6) | +25.0% | ||||||
| Free cash flow | (25) | (28) | (49) | (55) | (72) | (106) | (111) | (125) | 134 | (71) | (117) | +12.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 63 | 85 | 168 | 224 | 611 | 500 | 422 | 397 | 666 | 592 | 441 | +28.2% | |||||
| Net debt | (60) | (86) | (171) | (229) | (626) | (511) | (427) | (415) | (718) | (658) | (509) | +30.4% | ||||||
| Shareholders’ equity | 57 | 80 | 161 | 219 | 611 | 507 | 420 | 397 | 414 | 174 | 48 | +13.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (35.09) | (42.78) | (43.45) | (29.76) | (20.16) | (22.09) | (27.43) | (33.72) | (28.78) | (37.19) | (46.73) | (2.1) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (39.66) | (51.83) | (50.19) | (33.25) | (21.60) | (23.35) | (29.31) | (37.34) | (42.91) | (94.82) | (167.71) | (55.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 25 | 32 | 46 | 60 | 89 | 121 | 133 | 142 | 192 | 260 | — | +29.7% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.26 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Kura Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DBVT DBV Technologies S.A. | $615.8M | — (loss-making) | — | −42.86% (below 0%: shrinking) | n/m | −64.93% (below 0%: shrinking) | 100.00% | (4,043.75%) | Compare |
| CADL Candel Therapeutics, Inc. | $615.2M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| HELP Cybin Inc. | $613.0M | — (loss-making) | — (loss-making) | — | n/m | −25.60% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GERN Geron Corporation | $610.4M | — (loss-making) | — (loss-making) | +27.45% (above 0%: growing) | n/m | +176.13% (above 0%: growing) | 89.95% | 9.63% | Compare |
| DSGN Design Therapeutics, Inc. | $605.2M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KURA Kura Oncology, Inc. | $604.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | |
| AVBP ArriVent BioPharma, Inc. | $603.0M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| IMMX Immix Biopharma, Inc. | $596.9M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | Compare |
| OBX Obsidian Therapeutics, Inc | $593.0M | — | — | — | n/m | — | — | 0.00% | Compare |
| Median of peers | $607.8M | — | — | 0.00% | — | −51.51% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 10 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 4.74m | 6.49m | 83.72 |
| 2024 | 6.24m | 4.23m | 70.19 |
| 2023 | 5.25m | 5.95m | 115.87 |
Ownership
Directors and executive officers, together
7.60%
BVF Partners L.P.
9.80%
Suvretta Capital Management, LLC
8.50%
BlackRock, Inc.
7.10%
Armistice Capital
5.60%
State Street Corporation
5.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement